Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma
Metrics: PDF 1105 views | HTML 1374 views | ?
Li-Juan Wang1,*, Kai-Liang Zhang2,*, Ning Zhang3,*, Xiang-Wei Ma3, Su-Wen Yan3, Dong-Hua Cao3, Sheng-Jia Shi3
1Department of Oncology, The First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, 710061, Shaanxi Province, P.R. China
2Deparment of Orthopedics, No. 88 Hospital of PLA, Tai’an, 271000, Shandong Province, P.R. China
3Deparment of Aristogenesis, No. 202 Hospital of PLA, Shenyang, 110003, Liaoning Province, P.R. China
*These authors have contributed equally to this work
Sheng-Jia Shi, e-mail: email@example.com
Dong-Hua Cao, e-mail: firstname.lastname@example.org
Keywords: serum miR-26a, diagnostic, prognosis, cholangiocarcinoma
Received: February 26, 2015 Accepted: May 18, 2015 Published: May 29, 2015
In order to determine the diagnostic and prognostic value of miR-26a in Cholangiocarcinoma (CCA), we compared miR-26a levels in serum from 66 CCA patients and 66 healthy controls, which was followed by serum analysis between the pre-operative serum and post-operative serum of these CCA patients. We found the concentration levels of miR-26a in serum of CCA patients were significantly higher than that from healthy controls (P < 0.01). Furthermore, the concentration levels of miR-26a in the post-operative serum were significantly reduced when compared to the pre-operative serum (P < 0.001). High miR-26a in serum was correlated significantly with clinical stage, distant metastasis, differentiation status, and poor survival of CCA patients. More importantly, serum miR-26a was an independent prognostic marker for CCA. In conclusion, our results suggested that miR-26a in serum might be a potential and useful noninvasive biomarker for the early detection of CCA.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.